Parameters Cases (N=26) Controls (N=78) COR 95% CI p value
Gender Male 10 29 1.0    
Female 16  49 0.9  0.4-2.2 0.726
Age 15-30 6 8 1.0    
31-45 12 45 1.7 0.5-6.3 0.409
>45 8 23 0.8 0.3-2.1 0.612
BMI <18.5 20 41 3.0 1.1-8.3 0.033
≥18.5 6 37 1.0    
CD4+ cell count <50 15 22 13.0 (1.6-107.4)# 0.018
51-100 4 18 4.22 (0.4-41.5) 0.216
101-200 6 19 6.0 (0.7-54.8) 0.112
>200 1 19 1.0    
Type of TB SPPTB 10 55 1.0    
SNPTB 3 9 1.8 0.4-7.9 0.419
EPTB 13 14 5.1 1.8-14.0 0.002
Hepatitis B co-infection No 19 74 1.0    
Yes 7 4 6.8 1.8-25.7 0.005
ARV treatment No 7 28 1.0    
Yes 19 50 1.5 0.5-4.1 0.403
ARV Regimen EFV-based 7 18 1    
NVP based 11 29 0.9 0.3-3.0 0.965
Boosted PIs 1 3 0.9 0.76-9.70 0.901
WHO HIV/AIDS stage Stage 3 13 64 1.0    
Stage 4 13 14 4.6 1.7-11.9 0.002
Cotrimoxazole No 8 32 1.0    
Yes 18 46 1.6 0.6-4.0 0.354
CI: Confidence interval, COR: Crude Odd Ratio, NVP: nevirapine, EFV: efavirenz, PIs: Protease inhibitors #CI is so wide that it might not be considered useful in providing information about the value of CD4+ cells, although the OR is significant
Table 3: Bivariate analysis of risk factors for grade 1-4 anti-TB induced hepatotoxicity in TB/HIV co-infected patients.
Goto home»